| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/aaron-wealth-makes-big-bet-mbx-biosciences-11-million-share-purchase","as_of":"2026-04-22T15:21:13.336230+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/22/aaron-wealthmakes-a-big-bet-on-mbx-biosciences-with-a-1-1-million-share-purchase/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/aaron-wealth-makes-big-bet-mbx-biosciences-11-million-share-purchase","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_06bf8ff3d23bea0b","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/22/aaron-wealthmakes-a-big-bet-on-mbx-biosciences-with-a-1-1-million-share-purchase/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-22T15:50:46.513815+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsAaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences; estimated transaction value $37.35 million based on quarterly average pricing","fetched_title":"Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase | Nasdaq","final_url":"https://www.nasdaq.com/articles/aaron-wealth-makes-big-bet-mbx-biosciences-11-million-share-purchase","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/aaron-wealth-makes-big-bet-mbx-biosciences-11-million-share-purchase","source_event_id":"evt_ad16851aa37a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"c1872d2804fff3a9","kind":"unusual_volume","published_at":"2026-04-22T15:00:04+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 21, 2026","first quarter of 2026","end of 2025","March","third quarter","last September","April 20, 2026","April 22, 2026"],"entities":[{"asset_class":"equity_fund","name":"Aaron Wealth Advisors LLC","relevance":"high","symbol":"","type":"institutional_investor"},{"asset_class":"equity","name":"MBX Biosciences","relevance":"high","symbol":"MBX","type":"company"},{"asset_class":"regulation","name":"U.S. Food and Drug Administration (FDA)","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["The signal type requests an unusual volume ratio vs average, but the provided text does not include any baseline volume, average volume, or a computed volume ratio for MBX.","The article does not explicitly state whether the unusual volume is confirmed by news; it only reports the 13F purchase and related company/clinical-trial context.","No explicit catalyst is tied to the volume event itself; the only catalyst hypothesis provided is investor bullishness toward canvuparatide based on FDA feedback and planned Phase 3 timing."],"key_facts":["A SEC filing dated April 21, 2026 states Aaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences during the first quarter.","The estimated value of the trade was $37.35 million, based on the average closing price during the quarter.","The quarter-end value of the position rose by $32.66 million, incorporating both the net purchase and share-price movement.","After the filing, the fund held 1,168,176 shares valued at $34.87 million.","The MBX stake represented 1.98% of Aaron Wealth Advisors LLC\u2019s 13F reportable assets after the filing.","The article states the buy appears bullish for MBX\u2019s lead candidate canvuparatide.","The article says that in March, MBX told investors the FDA provided feedback supporting the planned Phase 3 trial.","The article states MBX intends to begin a Phase 3 study with canvuparatide in the third quarter.","The article describes canvuparatide as a long-acting replacement treatment for people with hypoparathyroidism and references Phase 2 results announced last September."],"numeric_claims":[{"label":"shares_bought","value":"1,098,176"},{"label":"estimated_trade_value_usd","value":"$37.35 million"},{"label":"position_value_increase_usd","value":"$32.66 million"},{"label":"shares_held_post_trade","value":"1,168,176"},{"label":"position_value_post_trade_usd","value":"$34.87 million"},{"label":"stake_percent_of_13F_reportable_assets","value":"1.98%"},{"label":"fund_assets_under_management_percent_trade","value":"2.12% of fund\u2019s 13F reportable assets"}],"primary_claim":"Aaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences in Q1 2026, with an estimated trade value of $37.35 million, and the position value increased by $32.66 million by quarter end.","relevance_score":0.62,"sentiment":"mixed","source_quality":"high","summary":"Aaron Wealth Advisors LLC disclosed a large first-quarter purchase of MBX Biosciences (NASDAQ: MBX), adding 1,098,176 shares and increasing its position value by about $32.66 million by quarter end. The article frames the buy as bullish on MBX\u2019s lead candidate canvuparatide, citing FDA feedback for a planned Phase 3 trial.","topics":["13F filing","large share purchase","MBX Biosciences","canvuparatide","Phase 3 trial","FDA feedback","clinical-stage biopharma"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsAaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences; estimated transaction value $37.35 million based on quarterly average pricing","tickers":[],"title":"Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase","url":"https://www.fool.com/coverage/filings/2026/04/22/aaron-wealthmakes-a-big-bet-on-mbx-biosciences-with-a-1-1-million-share-purchase/"}... |